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Abstract
Background: Atrial fibrillation (AF) is a common finding in patients with heart
failure and is well-known for its deleterious effects on cardiac function and
hemodynamics; however, there are gaps in knowledge regarding the impact of AF
on patients with left ventricular assist devices (LVADs).
Methods: In this study, we searched PubMed/Medline, Embase, and Cochrane
Library databases through September 2021 to find articles that assessed the
outcomes of AF in patients with LVADs.
Results: A total of 12 studies that underwent systematic review evaluated the
outcomes of 7853 adult patients. The meta-analysis analyzed findings from a total
of 1003 patients. Pooled findings indicated a 25% higher risk of mortality in
patients with AF as compared to those in sinus rhythm (P = .02). No statistically
significant differences in mortality were noted between patients with paroxysmal
AF or persistent AF (P = .13). No statistically significant differences were noted
between the groups in terms of bleeding (P = .70). There was an increased risk of
thromboembolism in patients with sinus rhythm compared to those with AF (P <
.001).
Conclusion: The presence of AF was not found to be associated with an
increased risk of bleeding or thromboembolism but may be associated with
increased mortality.

The VAD Journal: Atrial Fibrillation in LVAD

Page 1 of 15

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Introduction
Left ventricular assist devices (LVADs) have become an acceptable treatment
modality in patients with end-stage heart failure. Early survival rates with current
generation LVADs are comparable to heart transplantation, exceeding 80% at 1
year and 70% at 2 years.1,2 Although LVADs have significantly improved survival
rates and quality of life,3 there are several risks and adverse events associated
with their use, including pump thrombosis, major infections, cerebrovascular
accidents (CVA), and major bleeding.3 LVADs have been increasingly utilized
either as destination therapy or as a bridge to transplantation.3,4 However, many
patients clinically benefit from mechanical circulatory support as a bridge-torecovery, which offers support during the acute insult, or as a bridge-to-decision.4
Durable LVADs are considered in patients with New York Heart Association class
IV symptoms despite optimal medical therapy or those deemed dependent on
intravenous inotropes or temporary mechanical circulatory support.5 A summary of
current indications and contraindications is highlighted in Table 1.
Table 1. Indications and Contraindications for Left Ventricular Assist Device4

Indications

Contraindications

▪

▪
▪

▪
▪
▪

▪
▪
▪
▪

New York Heart Association class IIIIV despite optimal medical therapy
with poor quality of life
Inotrope-dependent advanced heart
failure
Progressive cardiac cachexia
Frequent hospitalizations for heart
failure with low aerobic capacity (peak
VO2 < 14 mL/kg/min or < 50%
predicted)
Circulatory intolerance to
neurohormonal antagonists
Diuretic refractoriness with worsening
renal function
Reversible end-organ dysfunction
secondary to low cardiac output
Non-responder or non-candidate for
mitral regurgitation repair

▪
▪
▪
▪
▪
▪
▪
▪

Irreversible neurologic injury
Systemic illness or disseminated
malignancy limiting survival
Coagulopathy disorders or
contraindications to
anticoagulation
Left ventricular or left atrial
thrombus (that cannot be removed
or treated)
Aortic aneurysm or dissection
Uncontrolled sepsis
Severe frailty unlikely to respond
to cardiac support
Medication non-compliance
Ventricular septal defect, severe
aortic or peripheral artery disease
Severe psychiatric illness

In the general population, atrial fibrillation (AF) is a known risk factor for mortality
and morbidity.6 In the United States alone, at least 3 to 6 million people have AF,
and the numbers are projected to reach ~6 to 16 million by 2050.6 The presence of
atrial arrhythmias is diagnosed in approximately 21-54% of patients before LVAD
implantation.7 Several studies have demonstrated an increased risk of death and
heart failure-related re-hospitalization in LVAD patients with AF with conflicting
results.8,9 This study aimed to update the findings of prior meta-analyses by
exploring the clinical outcomes of patients after LVAD implantation with AF
compared to patients with sinus rhythm.
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Methods
The study was designed following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.10 The study sought articles that
analyzed patients 18 years and older who underwent LVAD placement. Any
patient with valvular, non-valvular, paroxysmal, persistent, and permanent atrial
fibrillation was included in the study.

Selection Criteria/Search Strategy
We searched PubMed/Medline, Embase, and Cochrane Library databases for
articles published before September 2021. The medical subject headings “heartassist device,” “left ventricular assist device,” “atrial fibrillation,” and “atrial
arrhythmias” were used to extract relevant articles matching the study objective.
Two authors autonomously explored titles, abstracts, and full-text studies matching
the selection criteria. The blinding of the article selection process between authors
was followed by an independent assessment by a third reviewer.
We included randomized controlled trials, prospective, retrospective studies, case
reports, case series, and descriptive studies. We excluded review articles,
conference papers, abstracts, guidelines, systematic reviews, and meta-analyses.
Studies that did not look at outcomes were excluded.

Clinical Outcomes
The outcomes of this systematic review and meta-analysis included all-cause
mortality, thromboembolism, and major bleeding. Mortality is defined as either 30day or in-hospital mortality. CVA, arterial thromboembolism, LVAD pump
thrombosis, and transient ischemic attack were all classified as thromboembolism
events. Major bleeding was defined in this review according to the Interagency
Registry of Mechanically Assisted Circulatory Support definition or intracranial
hemorrhage. Gastrointestinal bleeding was reported separately.

Data Extraction and Quality Assessment
The extracted data were exported to RevMan 5.4 to remove duplicate articles. Two
independent authors used Microsoft Excel spreadsheets for data extraction.11
Table 2 elaborates on the baseline characteristics of the included studies. All
included articles were published in peer-reviewed journals. Without randomized,
controlled trials, we included cohort studies (retrospective and prospective)
reporting the incidence of post-operative right heart failure, unplanned right
ventricular assist device, bleeding (i.e., gastrointestinal bleeds), stroke, and
mortality. Clinical outcomes, study design, and sample size were extracted and
listed in Table 3. Two authors assessed study quality using the Newcastle-Ottawa
Scale.12
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Table 2. Baseline Characteristics of Patients with Left Ventricular Assist Devices and Paroxysmal or Persistent Atrial Fibrillation. As
available, information from studies is presented in a tabular format. Age and body mass index are presented as mean  standard deviation, median
(interquartile range), or as noted. The rest of the data is presented as the number (frequency).
Type
Total Number of
Patients
PAF
Number of
patients

Age, years

Hickey
et al.7

Enriquez
et al.8

Oezpeker
et al.9

Hayashi
et al.13

Noll et
al.14

Deshmukh
et al.15

Hawkins
et al.22

Kurihara
et al.23

Pedde et
al.24

Stulak et
al.25

Xia et
al.17

Xuereb
et al.26

249

106

322

110

418

47

1064

526

769

389

3,909

240

90
(36.1%)

36 (34%)

302
(72.2%)

13 (27.7%)

121
(11.4%)

229
(43.5%)

558
(72.6%)

389
(100%)

838
(21.4%)

78
(32.5%)

117
(36.3%)
205
(63.7%)

40
(36.3%)
19
(17.3%)
51
(46.4%)

34
(72.3%)

943
(88.6%)

297
57.0%)

211
(27.4%)

162
(67.5%)

62.7 (54.571.0)

58.0 (52.064.0)

58.5 
11.1

60.3
(12.5)

60.0 (19.079.0)

3071
(78.6%)
485
(57.9%) >
65yrs

9 (69.0%)

91
(75.2%)

186
(81.2%)

463
(83.0%)

308
(79.2%)

695
(82.0%)

64
(82.1%)

29.0 (25.035.0)

28  6.7

26.7  5.5

PeAF

19 (17.9%)

Others

159
(63.9%)

51
(48.1%)

PAF

58.0 
14.0

59.4  9.8
61.0  8.3

PeAF
PAF
Male
PeAF
Body Mass
Index, kg/m2

201
(81.0%)

61.0 
12.0
60.0  9.3

29 (80.6%)
15 (78.9%)

105
(89.7%)

64.0  9.0
35
(87.5%)
17
(89.5%)

116
(27.8%)
59.0
(52.067.0)
83
(27.5%)

PAF

55.7 
11.4

27.7  6.1

21.4  1.8

PeAF

Indication

Bridge To
Transplant
Destination
Therapy

PAF

30 (83.3%)

8 (20.0%)

PeAF

15 (79.9%)

7 (37.0%)

PAF

7 (19.4%)

26 (65.0%)

PeAF

4 (20.1%)

10 (53.0%)

9 (67.0%)

123
(53.7%)

259
(66.6%)

106
(46.3%)

130
(33.4%)

400
(47.1%)

Valve Regurgitation

Moderate/Severe
Mitral
Regurgitation
Moderate/Severe
Tricuspid
Regurgitation

PAF

25 (63.0%)

PeAF

7 (37.0%)

PAF

15 (37.5%)

PeAF

6 (32.0%)
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62 (61.4%)

50 (21.8%)

46 (45.5%)

32 (14.0%)

29 (37.2%)
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Table 2 (Continued). Baseline Co-morbidities.
Study

Type

Hickey
et al.7

Enriquez
et al.8

Oezpeker
et al.9

Hayashi
et al.13

Noll
al.14

et

Deshmukh
et al.15

Hawkins
et al.22

Kurihara
et al.23

Pedde et
al.24

Stulak et
al.25

Xia
al.17

et

Xuereb
et al.26

Co-morbidities
Diabetes
Mellitus
Dyslipidemia

PAF
PeAF
PAF
PeAF

Hypertension

PAF
PeAF

Ischemic
Cardiomyopathy
Coronary Artery
Disease
Previous
Myocardial
Infarct
Coronary Artery
Bypass Graft
Chronic Kidney
Disease
Pulmonary
Disease/COPD
Thyroid
Disorder

91 (37.0%)

PAF

20 (55.6%)
9 (47.4%)

10 (25.0%)
30 (25.6%)

27 (68.0%)

191
(79.0%)

25 (63.0%)

PeAF

6 (46.0%)

69 (49.6%)

107
(46.7%)

107
(28.0%)

118
(14.1%)

39
(50.6%)

7 (37.0%)

166
(68.0%)

92 (37.0%)

42 (13.9%)

245 (63%)

13 (68.0%)

50 (42.7%)
16 (44.4%)
6 (31.6%)

11 (92.0%)

40 (13.2%)

5 (38.0%)

79 (65.3%)

147
(64.2%)

142
(37.0%)

66 (84.0%)

13 (68.0%)
16 (40.0%)

48 (41.0%)

62 (20.5%)

112
(48.9%)

241
(43.4%)

394
(47.4%)

24 (30.8%)

352 (42%)

41 (52.6%)

9 (47.0%)

PAF

54 (17.9%)

PeAF
PAF

50 (41.3%)

90 (36.1%)

PeAF
PAF

8 (6.8%)
3 (23.0%)

PeAF
PAF

17 (47.2%)

PeAF

12 (63.2%)

30 (9.9%)

PAF

6 (15.0%)

PeAF

2 (11.0%)

PAF

6 (46.0%)

33 (14.4%)

4 (31.0%)

6 (32.0%)
PeAF
COPD: Chronic obstructive pulmonary disease; PAF: Paroxysmal Atrial Fibrillation; PeAF: Persistent Atrial Fibrillation
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Table 3: Systematic Review of Paroxysmal and Persistent Atrial Fibrillation.

Study

Study
Design

Patients

Objective

13

To determine the
incidence, predictors,
and outcomes of
postoperative AF in
patients undergoing
LVAD implantation

Summary of Results
Paroxysmal AF was:

Deshmukh
et al.15

Enriquez et
al.8

Hawkins et
al.22

Hayashi et
al.13

Hickey et
al.7

Retrospective
Cohort

Retrospective
Cohort

Retrospective
Cohort

Retrospective
Cohort

Retrospective
Cohort

•
•
•
•

55

To determine the effect
of AF on outcomes in
patients with HeartMate
II LVAD

•

121

To determine the risk of
mortality and resource
utilization of
postoperative AF after
LVAD placement

•

59

To investigate the effect
of AF on functional TR
and cardiovascular
events in patients with
HeartMate 3 LVAD

Kaplan-Meier analysis showed that patients with
Persistent AF had the worst survival (no AF 98%,
paroxysmal AF 98%, Persistent AF 84%, log-rank P =
.038) at 1 year.

•

90

To determine the
prevalence of AF and
its association with
cardiac outcomes in
patients with LVADs

No significant differences in risk of stroke or death for
patients with AF before or following LVAD insertion.
By multivariable logistic regression, female sex was
associated with an increased likelihood of newly
developed AF (29% vs. 9%, OR, 4.06; 95% CI, 1.61
to 10.27; P = .003).
After implantation, 139 patients had a stroke (78 non–
preoperative AF patients [26.2%], 61 preoperative AF
patients [26.6%]; P = .84).
Survival at 30 days, 6 months, 1 year, and 2 years
was 89.9%, 82.5%, 75.8%, and 68.0%, respectively,
for non-preoperative AF patients versus 90.8%,
78.2%, 72.5%, and 66.4%, respectively, for
preoperative AF patients (P = .60 for all time points, P
= .69 at 24 months).

•

•

•

Kurihara et
al.23

Retrospective
2290
Cohort

Predictive of recurrent new AF within 30 days of
LVAD implantation.
Associated with an increased risk of ischemic stroke
and device thrombosis (P = .01).
Not associated with increased mortality, length of
stay, or thrombotic complications within 30 days of
device implantation.
Persistent AF was an independent predictor of the
composite endpoint of death or HF hospitalization
(HR: 3.54; 95% CI: 1.52 to 8.25; P < .01).
Paroxysmal AF was not associated with increased
mortality,
HF
hospitalization,
bleeding,
or
thromboembolism
Paroxysmal AF was not associated with operative
mortality or stroke but was associated with major
morbidity (OR, 2.5; P = .0004) and unplanned right
ventricular assist device (OR, 2.9; P = .01).

To determine whether
preoperative AF was
associated with inferior
outcomes

•

The VAD Journal: Atrial Fibrillation in LVAD

Page 6 of 15

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Table 3 (continued): Systematic Review of Paroxysmal and Persistent Atrial Fibrillation.
Study

Study
Design

Patients

Objective

Summary of Results
•

To describe the burden
of AF/Atrial Flutter in
patients with LVADs
and to evaluate the
impact of rhythm control
strategies

•

•

117

To compare the risk of
thrombotic and
hemorrhagic
complications as well as
overall survival during a
2-year follow-up period
in patients with LVADs
with or without
permanent AF

•

558

To determine if
preoperative AF in
patients with LVADs
exhibit a higher rate of
pump thrombosis and
TE than those in SR

The cumulative incidence of TE was 8.4% (95% CI
6.0–10.7%) after one year and 10.7% (95% CI 8.0–
13.4%) after two years. The difference in the
incidence between the SR and AF groups was not
significant (P = .163)

•

389

To identify and examine
the effect of
preoperative AF
patients who underwent
implantation of CFLVAD and had
preoperative AF

TE events for patients with no preoperative AF and
no GI bleeding was 17%, preoperative AF and no GI
bleeding was 24%, no preoperative AF and GI
bleeding was 36%, and preoperative AF and GI
bleeding was 45% (P < .001).

•

485

To evaluate the
association of
preoperative AF with
thromboembolic events
and patient survival

Patients with AF had a higher rate of bleeding
events; 617 bleeding events occurred in 323 (38.5%)
patients with AF.
AF was not significantly associated with TE
(adjusted HR, 0.95; 95% CI, 0.91-1.31)

Retrospective
Noll et al.14

302
Cohort

Oezpeker
et al.9

Pedde et
al.24

Stulak et
al.25

Retrospective
Cohort

Retrospective
Cohort

Retrospective
Cohort

Retrospective
Xia et al.17
Cohort

AF/AFL patients had fewer thromboembolic events
(13% vs. 23%; P < .01).
Paroxysmal or persistent AF/AFL was present in 238
patients (57%), and rhythm control exposure (n =
166, 70%) was not associated with decreased
mortality (39% vs 43%; P = .57), thromboembolism
(13% vs 17%; P = .41), or bleeding (49% vs 39%; P
= .16).
Patients with AF/AFL had similar mortality as those
without. AF/AFL had no association with the risk of
death, thromboembolism, or bleeding.
Two-year survival was 65.4% (n = 134) in the SR
group and 51.3% (n = 60) in the AF group.
Right heart failure was a more frequent cause of
death in the AF group than in the SR group (P =
.008).
The propensity score-adjusted two years HR of TE
and bleeding events were similar in both groups.

•

•
•

•
•

There was a similar incidence of stroke in patients
with and without AF: 12.8% versus 16%, (P = .803).
Retrospective
Xuereb et
•
Survival was also similar with 1-, 6-, 12- and 2478
months survivals of 96.2%, 91.7%, 84.5%, & 69.2%,
al.26
Cohort
respectively, in AF patients compared to 93.1%,
85%, 79.4% and 74.1% for non-AF, respectively (P =
.424).
AF: Atrial Fibrillation; AFL: Atrial Flutter; CF-LVAD: continuous flow- LVAD; CI: confidence interval; GI: Gastrointestinal; HR:
hazard ratio; LVAD: left ventricular assist device; OR: Odds Ratio; SR: Sinus Rhythm; TE: Thromboembolism
To determine the
impact of preoperative
AF on stroke, device
thrombosis, and
survival
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Statistical Analysis
A meta-analysis of the clinical outcomes was performed by calculating the odds
ratios (ORs) and 95% CIs (confidence intervals). The risk ratios (RRs) assessment
was performed through random effects methods to assess the risk of respective
outcome variables in the AF and sinus rhythm groups. Forest plots from included
studies reflected total patients versus those with reported clinical endpoints. The Isquare values indicated the heterogeneity of the study outcomes. Minimal,
moderate, and high heterogeneity were defined by the I-square ranges of 0-30%,
31-60%, and 61-100%, respectively. A P-value of ≤ .05 was considered statistically
significant.

Results
Included Studies
The initial search across PubMed/Medline, Embase, and Cochrane Library
resulted in the selection of 896 articles matching the inclusion criteria. After
excluding duplicate articles, 844 unique studies underwent further screening based
on their titles and abstracts. Sixty-five studies were retained after the screening
process, requiring further assessment based on the full-text articles. Twelve
studies were included in the systematic review, and five studies were used for
meta-analysis. A total of 12 studies that underwent systematic review evaluated
the outcomes of 7853 adult patients. The meta-analysis analyzed findings from a
total of 1003 patients.

All-Cause Mortality: Atrial Fibrillation Versus Sinus Rhythm
All-cause mortality was examined in 521 patients in the AF group and 457 in the
sinus rhythm group from five studies (Noll, et al., Enriquez, et al., Oezpeker, et al.,
Deshmukh, et al., and Hayashi, et al.).8,9,13-15 The pooled findings indicated a 25%
higher mortality risk in patients with AF compared to those with sinus rhythm (RR,
1.25; CI, 1.04-1.50; P = .02) (Figure 1A). There was minimal heterogeneity in
findings from respective studies (I-square =0%; P = .53), which was not statistically
significant. The asymmetry of the funnel plot indicated a risk of publication bias in
these reported findings (Figure 1B).

A

B

Figure 1. All-cause Mortality. A) Forest Plot; B) Funnel Plot
The VAD Journal: Atrial Fibrillation in LVAD
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All-Cause Mortality: Paroxysmal Atrial Fibrillation Versus Persistent
Atrial Fibrillation
All-cause mortality was examined further in three studies (Enriquez, et al.,
Hayashi, et al., Noll, et al.) comparing persistent AF and paroxysmal AF.8,13,14 The
pooled findings from these studies indicated an 85% higher risk of mortality in
patients with persistent AF compared to those with paroxysmal AF (RR, 1.85; CI,
0.84-4.08; P = .13) (Figure 2A); however, this increased risk was found to be
statistically insignificant. There was moderate heterogeneity in the included studies
(I-square = 52%; P = .13). The asymmetrical funnel plot indicated a risk of
publication bias in the findings related to all-cause mortality (Figure 2B).

A

B

Figure 2. All-cause Mortality between Paroxysmal and Persistent Atrial
Fibrillation. A) Forest Plot; b) Funnel Plot.

Thromboembolism Analysis for Sinus Rhythm versus Atrial
Fibrillation
Thromboembolism was evaluated in 218 patients in the sinus rhythm group and
416 patients in the AF group from the same three studies.8,13,14 The pooled
outcomes indicated an increased risk of thromboembolism in patients with sinus
rhythm compared to those with AF (RR, 2.04; CI 1.38-3.02; P < .001) (Figure 3A).
There was minimal heterogeneity (I-square = 7%; P = .34) that lacked statistical
significance. The asymmetrical funnel plot did not rule out the risk of publication
bias (Figure 3B).

A

B

Figure 3. Risk of Thromboembolism in Atrial Fibrillation versus Sinus
Rhythm. A) Forest Plot; b) Funnel Plot.
The VAD Journal: Atrial Fibrillation in LVAD

Page 9 of 15

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Risk of Thromboembolism in Paroxysmal AF versus Persistent AF
Thromboembolism was evaluated in 226 patients in the paroxysmal AF group and
126 patients in the persistent AF group.8,13,14 Pooled results from three studies
indicated a 35% reduced risk of thromboembolism in patients with paroxysmal AF
as compared to those with persistent AF (RR, 0.65; CI, 0.15-2.82; P = .57) (Figure
4). The pooled results lacked statistical significance. There was moderate
heterogeneity in findings from these studies (I-square = 58%; P = .09).

Figure 4. Forest Plot of Risk of Thromboembolism in Paroxysmal versus
Persistent Atrial Fibrillation

Bleeding Risk in Sinus Rhythm versus Atrial Fibrillation
Bleeding risk was assessed in 167 patients in the sinus rhythm group and 293
patients in the AF group.8,14 The pooled results from two studies revealed a 12%
higher risk of general bleeding in patients with AF compared to those with sinus
rhythm (RR, 1.12; CI, 0.63-2.00; P = .70) (Figure 5). This result, however, lacked
statistical significance. The pooled outcomes revealed moderate heterogeneity (Isquare = 72%) that lacked statistical significance (P = .06).

Figure 5. Forest Plot of General Bleeding in Sinus Rhythm versus Atrial
Fibrillation
The VAD Journal: Atrial Fibrillation in LVAD
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Bleeding Risk for Paroxysmal AF versus Persistent AF
Bleeding risk was assessed in two studies comparing paroxysmal AF and
persistent AF.8,14 The pooled results indicated an 8% higher risk of general
bleeding in patients with paroxysmal AF compared to those with persistent AF
(RR, 1.08; CI, 0.82-1.42; P = .58) (Figure 6). This finding was statically
insignificant. The outcomes revealed minimal heterogeneity (I-square = 0%) that
lacked statistical significance (P = .57).

Figure 6. Forest Plot of General Bleeding Risk in Paroxysmal versus
Persistent Atrial Fibrillation

Risk of Gastrointestinal Bleeding
Gastrointestinal bleeding was assessed in 167 patients in the sinus rhythm group
and 293 patients in the AF group.8.14 The pooled outcome from two studies
indicated a 24% lower risk of gastrointestinal bleeding in patients with sinus rhythm
compared to those with AF (RR, 0.76; CI, 0.41-1.43; P = .40) (Figure 7). The
results were statistically insignificant. The pooled findings revealed moderate
heterogeneity (I-square = 70%) but lacked statistical significance (P = .07).

Figure 7. Forest Plot of Gastrointestinal Bleeding
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Discussion
Our study reports that AF is associated with an increased risk of all-cause mortality
but not with thromboembolism or bleeding. This study builds on the results from a
prior meta-analysis by Usman et al.16, who examined studies that attributed the
increased risk of mortality in patients with LVADs to the presence of AF. We add to
their findings by including all patients with reported AF both pre-operatively and
post-operatively. Our findings support those of Oezpeker et al.9 and Xia et al.17,
who reported a higher mortality rate in patients with AF. A study by Hickey et al.7
found no significant differences in mortality in patients with AF before and after
LVAD implantation. However, more of Hickey’s study patients were taking
amiodarone (35%) or beta-blockers (43%) before LVAD implantation for
documented ventricular arrhythmia, which may have suppressed the development
of AF or AF with rapid ventricular rate.
Only three studies were found that categorized outcomes by the type of AF.
Enriquez et al.8 confirmed an increase in mortality in patients with persistent AF,
suggesting that there may be an arrhythmic burden. A more recent study by Noll et
al.14 found no difference in all-cause mortality between patients with paroxysmal or
persistent AF. In our study, although there was a trend toward increased mortality
in the persistent AF group, it did not reach statistical significance. Many studies in
our meta-analysis did not provide subgroup analysis between the types of AF to
conclude if rhythm burden could potentially affect the outcome of LVAD
implantation. Future studies should include a subgroup analysis of the types of AF
to evaluate further the discrepancy found among these studies.
Potential mechanisms to explain why AF might be associated with increased
mortality risk in patients with LVADs include the development of right ventricular
failure because of AF with rapid ventricular rates.9,18 Although our current study
does not provide direct evidence of this, Oezpeker et al. did find a significantly
higher incidence of right heart failure as a cause of death in the AF group.
Hottiguader et al.18 reported from a case series that catheter ablation led to the
resolution of right heart failure in these patients and improved survival.
Our study found no difference in the incidence of thromboembolism between the
patients with paroxysmal and persistent AF. This supports the findings from the
meta-analysis by Usman et al.16 and Tantrachoti et al.19, who reported no
association between pre-operative AF and thromboembolism. Similarly, our results
are inconsistent with the additive effect theory that therapeutically anticoagulated
LVAD patients with AF are at an increased risk of thromboembolic events. Other
studies suggested a reduced association.8 To date, there is no clinical trial
available to support decision-making regarding target international normalized
ratio, rhythm control strategies, or left atrial appendage procedures in this
subgroup of patients.20 The study by Enriquez et al.8 found that patients with AF
were on a higher intensity of anticoagulation (INR goal of 2.0–2.5) compared to
those without AF (INR goal of 1.5–2.0), and the patients with AF developed
thromboembolic complications despite higher INR levels (2.7 versus 1.54; P =
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.003).8 Hickey et al. noted that the majority of individuals who suffered a stroke in
their study did so in the setting of subtherapeutic INR levels.7 The optimal INR goal
in LVAD-treated patients with AF has not yet been established.21
Our study did not find a significant difference in the risk of bleeding between the
two groups. Interestingly, Usman et al. reported an increased risk of
gastrointestinal bleeding in patients with pre-operative AF. The absence of this
association in our results suggests that other factors may have contributed to this
increased risk. The age differences, risk of bleeding, and comorbidities were not
accounted for in prior studies.

Limitations
Our study has several limitations. Most of the pooled studies were retrospective
and observational and likely have residual confounding; this results in studies
being prone to bias. Several discrepancies in baseline demographics and clinical
characteristics may have also affected the results. All patients with AF after LVAD
implantation were included regardless of having AF before implantation or after. In
addition, there are variations between the studies in terms of anticoagulation
protocols, median follow-up time, and the type of LVAD implanted.

Conclusion
This meta-analysis showed that AF in patients with LVADs is associated with an
increased mortality rate and is not associated with increased bleeding or
thromboembolism. However, as previously mentioned, interpretation of our results
is limited by the potentially confounding factors from retrospective studies. Our
observations highlight the current uncertainty regarding arrhythmias in patients
with LVADs and the need for future research as well as larger prospective studies.
Given the complexity of the LVAD population, the clinical implications and
management strategies of AF can be challenging in clinical practice. Important
knowledge gaps about arrhythmias in LVAD recipients remain, and determining
the benefit of any particular treatment remains challenging given the paucity of
data available.
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